E Fund Management Co. Ltd. purchased a new stake in Anika Therapeutics, Inc. (NASDAQ:ANIK) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,134 shares of the biotechnology company’s stock, valued at approximately $46,000.
Several other hedge funds have also added to or reduced their stakes in the company. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its position in shares of Anika Therapeutics by 1.9% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 13,336 shares of the biotechnology company’s stock valued at $543,000 after purchasing an additional 252 shares during the last quarter. State of Tennessee Treasury Department grew its position in shares of Anika Therapeutics by 4.6% in the first quarter. State of Tennessee Treasury Department now owns 8,731 shares of the biotechnology company’s stock valued at $356,000 after purchasing an additional 384 shares during the last quarter. Vantage Consulting Group Inc acquired a new stake in shares of Anika Therapeutics in the fourth quarter valued at approximately $27,000. Winslow Evans & Crocker Inc. acquired a new stake in shares of Anika Therapeutics in the fourth quarter valued at approximately $27,000. Finally, Swiss National Bank grew its position in shares of Anika Therapeutics by 1.9% in the first quarter. Swiss National Bank now owns 32,500 shares of the biotechnology company’s stock valued at $1,326,000 after purchasing an additional 600 shares during the last quarter. Institutional investors and hedge funds own 92.51% of the company’s stock.
Separately, Zacks Investment Research upgraded shares of Anika Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 6th.
Shares of NASDAQ ANIK opened at $44.76 on Friday. Anika Therapeutics, Inc. has a 1 year low of $31.55 and a 1 year high of $48.37. The stock’s 50 day moving average price is $42.54. The firm has a market capitalization of $644.14 million, a price-to-earnings ratio of -23.68, a P/E/G ratio of 24.26 and a beta of 1.21.
Anika Therapeutics (NASDAQ:ANIK) last announced its earnings results on Wednesday, May 5th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.19. Anika Therapeutics had a negative net margin of 20.83% and a negative return on equity of 0.98%. The firm had revenue of $34.29 million for the quarter, compared to analyst estimates of $32.39 million. Analysts predict that Anika Therapeutics, Inc. will post 0.19 EPS for the current fiscal year.
About Anika Therapeutics
Anika Therapeutics, Inc, together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses.
Featured Story: What is a Market Correction?
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics, Inc. (NASDAQ:ANIK).
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.